United States Ovarian Cancer Therapeutics Market, By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Others), By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, and Sex Cord-Stromal Tumor), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.06 Billion
CAGR (2026-2031)	9.53%
Fastest Growing Segment	Chemotherapy
Largest Market	South
Market Size (2031)	USD 1.83 Billion

Market Overview

The United States Ovarian Cancer Therapeutics Market will grow from USD 1.06 Billion in 2025 to USD 1.83 Billion by 2031 at a 9.53% CAGR. Ovarian cancer therapeutics encompass pharmacological interventions such as chemotherapy, PARP inhibitors, and immunotherapies designed to treat malignancies arising in the ovaries. The United States market is primarily supported by the introduction of targeted therapies that offer improved clinical outcomes and the increasing adoption of combination regimens. Additionally, the growing geriatric population and heightened awareness regarding early disease detection further strengthen the demand for effective oncological treatments.

The substantial burden of the disease highlights the critical necessity for these medical interventions. According to the American Cancer Society, in 2025, an estimated 20,890 new cases of ovarian cancer will be diagnosed in the United States. However, market expansion is significantly impeded by the high cost of novel therapeutics which limits widespread patient access and places significant financial strain on healthcare payers and insurance providers.

Key Market Drivers

The United States Ovarian Cancer Therapeutics Market is undergoing a significant transformation driven by the emergence of novel Antibody-Drug Conjugates (ADCs). These therapies represent a critical shift from conventional chemotherapy by utilizing targeted antibodies to deliver cytotoxic payloads directly to tumor cells, thereby addressing the urgent need for effective treatments in platinum-resistant cases. The commercial success of mirvetuximab soravtansine (Elahere), which targets folate receptor alpha, exemplifies the rapid integration of this class into clinical practice. According to AbbVie Inc., October 2024, in the 'Third-Quarter 2024 Financial Results', global net revenues for Elahere reached $139 million in the third quarter alone. This substantial revenue generation highlights the immediate adoption of ADCs by oncologists and their potential to become a cornerstone of therapeutic regimens for patients with limited options.

Simultaneously, the accelerated adoption of PARP inhibitors and targeted therapies continues to serve as a primary engine for market expansion. These oral interventions have reshaped maintenance treatment protocols, particularly for women with BRCA mutations or homologous recombination deficiency, by significantly delaying disease recurrence. According to AstraZeneca Plc, February 2024, in the 'Full Year and Q4 2023 Results', the leading PARP inhibitor Lynparza generated total revenue of $2,811 million in 2023, reflecting its sustained dominance and widespread clinical utility. This commercial momentum is further bolstered by federal initiatives aimed at sustaining the development pipeline; according to the U.S. Department of Defense, in 2024, the Ovarian Cancer Research Program received a fiscal year appropriation of $45 million to support high-impact research projects, ensuring a continuous flow of innovation into the therapeutics market.

Download Free Sample Report

Key Market Challenges

The high cost of novel therapeutics constitutes a significant barrier to the expansion of the United States ovarian cancer therapeutics market. Developing targeted therapies and immunotherapies involves extensive research and manufacturing expenses, which translates into elevated market prices. These costs create substantial financial toxicity for patients, often forcing them to delay or abandon essential treatment due to high out-of-pocket expenditures. Consequently, reduced patient adherence directly diminishes the consumption volume of these drugs, thereby hampering overall market revenue growth despite the clinical efficacy of these treatments.

Furthermore, these elevated price points impose pressure on healthcare systems and insurance providers. Payers frequently implement strict reimbursement policies, such as rigorous prior authorization requirements, to manage these expenses. According to the American Cancer Society, in 2025, the list price for many prescription medicines used in cancer care is more than $100,000 annually. Such high financial benchmarks limit the widespread adoption of new regimens, as economic constraints restrict access for a significant portion of the patient population, effectively stifling the market’s potential trajectory.

Key Market Trends

The integration of immunotherapy combinations into treatment protocols is reshaping the management of advanced ovarian cancer, particularly for patients without BRCA mutations who have historically faced limited therapeutic options. Pharmaceutical developers are prioritizing regimens that pair immune checkpoint inhibitors with chemotherapy or PARP inhibitors to enhance anti-tumor responses and extend survival in difficult-to-treat populations. This strategic pivot aims to potentiate immune system activity to overcome the resistance mechanisms often seen with single-agent therapies. According to Fierce Pharma, October 2025, in a report covering the ESMO Congress, Merck’s Keytruda-based combination regimen demonstrated a median progression-free survival of 8.3 months in patients with platinum-resistant disease, marking a significant clinical improvement over standard chemotherapy benchmarks.

Simultaneously, the market is witnessing the emergence of novel mechanisms targeting specific oncogenic pathways in platinum-resistant subtypes, such as low-grade serous ovarian cancer (LGSOC). This shift moves beyond traditional cytotoxic agents toward precision therapies that inhibit the RAS/MAPK signaling cascade, directly addressing the molecular drivers of recurrence in patients with distinct genomic profiles. This approach validates the commercial viability of developing treatments for niche patient segments that were previously underserved by broad-spectrum interventions. According to Verastem Oncology, May 2025, in the announcement regarding the FDA approval of Avmapki and Fakzynja, the combination therapy achieved a confirmed overall response rate of 44% in patients with KRAS-mutated recurrent LGSOC, establishing a new standard for targeted intervention in this rare indication.

Segmental Insights

Based on recent market intelligence, Chemotherapy has emerged as the fastest-growing segment in the United States Ovarian Cancer Therapeutics Market. This rapid expansion is primarily driven by the escalating incidence of ovarian malignancies, which substantially increases the volume of patients requiring platinum-based agents as the definitive standard of care. Additionally, the segment’s growth is catalyzed by the increasing regulatory approval of combination protocols that utilize chemotherapy as a foundational component alongside novel targeted agents. Consequently, the indispensable role of cytotoxic drugs in both first-line and recurrent treatment settings continues to propel significant market momentum.

Regional Insights

The Southern United States maintains a dominant position in the ovarian cancer therapeutics market driven by a high concentration of the target patient population. States such as Florida possess substantial geriatric demographics, contributing to elevated disease incidence rates recognized by the Centers for Disease Control and Prevention. Additionally, the region benefits from established healthcare infrastructure, including the University of Texas MD Anderson Cancer Center, which expands patient access to specialized care and clinical trials. These demographic and clinical factors collectively support the high demand for therapeutic interventions across the South.

Recent Developments

• In December 2024, GSK reported positive headline results from the Phase 3 FIRST-ENGOT-OV44 clinical trial, which evaluated the combination of its immuno-therapy, Jemperli, and its PARP inhibitor, Zejula, as a first-line maintenance treatment. The study focused on patients with advanced ovarian, fallopian tube, or primary peritoneal cancer and successfully met its primary endpoint of progression-free survival. The Senior Vice President of Oncology R&D at GSK stated that the data demonstrated a statistically significant benefit when adding the immuno-therapy to standard-of-care chemotherapy, reinforcing the potential of this combination strategy to improve outcomes for patients with newly diagnosed disease.
• In December 2024, Merck announced that its Phase 3 KEYLYNK-001 trial met the primary endpoint of progression-free survival in patients with advanced epithelial ovarian cancer. The study investigated the efficacy of combining the company’s anti-PD-1 therapy, Keytruda, with the PARP inhibitor Lynparza, which is co-developed in collaboration with AstraZeneca, as a first-line treatment for patients without BRCA mutations. The Vice President of Global Clinical Development at Merck Research Laboratories noted that the trial showed a clinically meaningful improvement compared to chemotherapy alone, marking a significant advancement in identifying effective combination regimens for this challenging indication.
• In October 2024, Verastem Oncology completed the rolling submission of its New Drug Application to the U.S. FDA for a novel combination therapy designed to treat recurrent low-grade serous ovarian cancer. The application sought accelerated approval for the concurrent use of avutometinib and defactinib in adult patients with KRAS mutant disease who have undergone at least one prior systemic therapy. The President of Verastem Oncology characterized the submission as a significant milestone toward providing a potential first-in-class treatment for this rare and distinct form of ovarian cancer, which historically lacks specifically approved therapeutic options.
• In March 2024, AbbVie announced that the U.S. Food and Drug Administration (FDA) granted full approval to its antibody-drug conjugate, Elahere, for the treatment of platinum-resistant ovarian cancer. This regulatory decision was supported by data from the confirmatory Phase 3 MIRASOL trial, which demonstrated a statistically significant improvement in overall survival and a reduction in the risk of tumor progression compared to chemotherapy. The approval established the therapy as the first antibody-drug conjugate in the United States specifically authorized for patients with folate receptor alpha-positive ovarian, fallopian tube, or primary peritoneal cancer who have received prior systemic therapies.

Key Market Players

• AstraZeneca
• Genentech Inc
• GlaxoSmithKline PLC
• Janssen Biotech Inc
• Merck & Co Inc
• Novartis International AG
• Pfizer Inc
• Regeneron Pharmaceuticals Inc
• AbbVie Inc
• ImmunoGen Inc

By Treatment	By Tumor Type	By Distribution Channel	By Region
Chemotherapy Radiation Therapy Immunotherapy Hormonal Therapy Others	Epithelial Ovarian Cancer Ovarian Low Malignant Potential Tumor Germ Cell Tumor Sex Cord-Stromal Tumor	Hospital Pharmacies Retail Pharmacies Online Pharmacies	Northeast Midwest South West

Report Scope:

In this report, the United States Ovarian Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Ovarian Cancer Therapeutics Market, By Treatment:

• Chemotherapy
• Radiation Therapy
• Immunotherapy
• Hormonal Therapy
• Others

• United States Ovarian Cancer Therapeutics Market, By Tumor Type:

• Epithelial Ovarian Cancer
• Ovarian Low Malignant Potential Tumor
• Germ Cell Tumor
• Sex Cord-Stromal Tumor

• United States Ovarian Cancer Therapeutics Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• United States Ovarian Cancer Therapeutics Market, By Region:

• Northeast
• Midwest
• South
• West